Chris Derk, MD
Basic profileChris Derk is a Rheumatology/Immunology physician affiliated with University of Pennsylvania. OpenAlex indexes 112 publications with 3,656 citations (h-index 33); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Sponsor: University of Pennsylvania
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GSKProgram year202525 paymentsResearch$77,396
- AstraZeneca UK LimitedProgram year20257 payments$32,200
- ZOLL Medical CorporationProgram year20251 payment$508
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Antiparasitic
26.6%Antimalarial26.6%Hydroxychloroquine Sulfate100%Part D≥60 patientsCancer & immunology
23.4%Folate Analog Metabolic Inhibitor9%Methotrexate100%Part D≥23 patientsTNF inhibitor5.6%Humira29%Humira Pen26%Humira(Cf) Pen25%Enbrel20%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
22.3%Corticosteroid21%Prednisone100%Part D≥54 patientsAminosalicylate1.3%Sulfasalazine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry
Proceedings of the National Academy of Sciences
2019 - Mortality and survival in systemic sclerosis: a review of recent literature
Current Opinion in Rheumatology
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Raquel Gur, MD
University of Pennsylvania
Howard Herrmann, MD
University of Pennsylvania
Robert Vonderheide, MD
University of Pennsylvania
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”